The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.

Osteoporos Int · 2022 · PMC8843904 · PMID 34601629

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Further stratified analyses suggested that the risk of MOF in MG patients was highest among those current users who received the highest cumulative dose of oral GC (≥ 7 g), although this did not reach statistical significance adj.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.